Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca teams with Heptares

AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders

AstraZeneca (AZ) has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders.

The deal includes a £3.8m payment to Heptares, which will also be eligible for royalties from any successful products, while AZ will gain the worldwide rights.

The collaboration will make use of Heptares' G protein-coupled receptors (GPCR) discovery expertise and proprietary technologies - including its StaR technology, which engineers stabilised receptors allowing GPCRs to be investigated.

GPCRs are one of the largest family of proteins, yet have an inherent instability when removed from cell membranes, according to a statement from AZ. 

Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AZ's small and large molecule portfolio, including projects from AZ's biologics unit, MedImmune.

Martin Mackay, president of research and development, AZ, said: "Our work will focus on a range of different diseases across our small and large molecule portfolio with the goal of discovering innovative treatments for patients in areas of medical need."

31st May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...